Express Pharma

Cipla posts PAT of Rs 343 crore in Q3 FY1516

1

Domestic sales reduced to Rs 1,194 crore

Cipla announced its unaudited consolidated financial results for the quarter ended December 31, 2015 (Q3). Income from operations grew by 12.3 per cent to Rs 3,107 crore, up from Rs. 2,765 crore. EBITDA decreased by 18.1 per cent to Rs 454 crore, down from Rs 554 crore. Profit after tax increased by 4.7 per cent to Rs 343 crore, up from Rs 328 crore.

Material cost is at 39.7 per cent of income from operations in Q3 FY1516 as compared to 35.8 per cent in Q3 FY1415. EBIDTA as percentage of income from operations decreased to 14.6 per cent in Q3 FY1516 from 20 per cent in Q3 FY1415. Profit after tax increased by 4.7 per cent to Rs 343 crore, up from Rs 328 crore in Q3 FY1415.

Domestic sales reduced by 0.4 per cent to Rs 1,194 crore during Q3 FY1516 from Rs 1,199 crore during Q3 FY1415. Exports of formulations increased by 28.5 per cent to Rs 1,833 crore during Q3 FY1516, from Rs 1,426 crore during Q3 FY1415. Exports of APIs decreased by 5.3 per cent to Rs 143 crore during Q3 FY1516, from Rs 151 crore during Q3 FY1415.

Comments are closed.